Heng Mei
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
25
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
60
PubMed author-name match
Trials
Studies that name Heng Mei as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:17 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07416032 · A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune ThrombocytopeniaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · not yet recruiting · Immune Thrombocytopenia (ITP) · principal investigator
- Early Ph1NCT07240974 · Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · recruiting · Relapsed/Refractory B-cell Malignancies · principal investigator
- Ph4NCT07189910 · Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITPUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · not yet recruiting · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Early Ph1NCT07101705 · An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · recruiting · Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) · principal investigator
- N/ANCT06790888 · Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid FailureUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · not yet recruiting · ITP - Immune Thrombocytopenia · study chair
- Ph1/Ph2NCT06735495 · CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic TumorsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · recruiting · B-Cell Lymphoblastic Leukemia/Lymphoma · principal investigator
- Ph1NCT06534021 · IASO-782 in Autoimmune Hematological DiseasesShanghai IASO Biotechnology Co., Ltd · recruiting · Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia · principal investigator
- Early Ph1NCT06519565 · Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · recruiting · Immune Thrombocytopenia · principal investigator
- N/ANCT06142175 · Relmacabtagene Autoleucel in Patients With LBCLShanghai Ming Ju Biotechnology Co., Ltd. · unknown · Large B-cell Lymphoma · principal investigator
- Ph2NCT05998928 · A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of TherapyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Multiple Myeloma · principal investigator
- Ph1NCT05765006 · CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus ErythematosusShanghai Ming Ju Biotechnology Co., Ltd. · unknown · Systemic Lupus Erythematosus · principal investigator
- Early Ph1NCT05722171 · Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd. · unknown · Relapsed/Refractory Acute Myeloid Leukemia · principal investigator
- Ph1NCT05445011 · Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid LeukemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · recruiting · Acute Myeloid Leukemia · principal investigator
- Early Ph1NCT05432401 · TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid LeukemiaPersonGen BioTherapeutics (Suzhou) Co., Ltd. · unknown · FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · principal investigator
- Ph4NCT05311930 · Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP PatientsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Primary Immune Thrombocytopenia · principal investigator
- Ph1NCT05170568 · PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesPersonGen BioTherapeutics (Suzhou) Co., Ltd. · unknown · CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · principal investigator
- Ph1NCT04823091 · Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT04796688 · Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma · principal investigator
- Ph1NCT04662099 · T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple MyelomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · CS1+ or BCMA+ Multiple Myeloma · principal investigator
- Ph1NCT04014881 · Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · CD123+ Acute Myeloid Leukemia · principal investigator
- Ph1NCT04014894 · ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and LymphomaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Leukemia, Lymphoma · principal investigator
- Ph1NCT04008381 · Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid LeukaemiaUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Acute Myeloid Leukemia · principal investigator
- Ph1NCT04008251 · Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesWuhan Sian Medical Technology Co., Ltd · unknown · Acute Lymphoblastic Leukemia, B Cell Lymphoma · principal investigator
- Ph1NCT04008394 · Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
- Ph1NCT04007978 · Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · unknown · B Cell Lymphoma, Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:17 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- 943 citationsRCR 43.3
- 340 citationsRCR 17.9
- 258 citationsRCR 5.6
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.J Hematol Oncol · 2021194 citationsRCR 9.5
- 128 citationsRCR 4.1
- Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.Ann Hematol · 2019110 citationsRCR 3.8
- Effect of copy number variants on outcomes for infants with single ventricle heart defects.Circ Cardiovasc Genet · 201386 citationsRCR 2.9
- Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study.Signal Transduct Target Ther · 202281 citationsRCR 7.1
- A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.J Hematol Oncol · 202167 citationsRCR 4.6
- 60 citationsRCR 9.8